Allarity Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 3.35 million compared to USD 3.08 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.501 USD | -9.71% | -18.67% | -95.45% |
24/05 | Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial | CI |
06/05 | Allarity Therapeutics Says Stockholders' Equity 'Significantly' Exceeds Nasdaq's $2.5 Million Minimum Rule | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-95.45% | 155K | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- ALLR Stock
- News Allarity Therapeutics, Inc.
- Allarity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023